Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Equillium Inc
(NQ:
EQ
)
1.090
+0.150 (+15.93%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Equillium Inc
< Previous
1
2
3
4
5
Next >
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 13, 2023
From
Equillium, Inc.
Via
Business Wire
Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday
December 27, 2022
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
December 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From
Equillium, Inc.
Via
Business Wire
Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research
December 06, 2022
Via
Benzinga
Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 Stocks Moving Premarket
December 07, 2022
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 71.3% to $0.7190 in pre-market trading after the company reported withdrawal of registration statement.
Via
Benzinga
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
December 06, 2022
From
Equillium, Inc.
Via
Business Wire
How Equillium Inc Could Help Lead The Fight Against Autoimmune Diseases
December 02, 2022
Equillium Inc. (NASDAQ: EQ) is a clinical-stage biotechnology company that focuses on immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders.
Via
Benzinga
Equillium Shares Ride Higher After Positive Data From Lead Asset In Kidney Inflammation
September 27, 2022
Via
Benzinga
Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal
September 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
On Friday, 72 companies hit new 52-week lows.
Via
Benzinga
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
November 14, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
November 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 03, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
November 02, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
October 26, 2022
From
Equillium, Inc.
Via
Business Wire
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
September 28, 2022
Gainers
Via
Benzinga
Why Is Equillium (EQ) Stock Soaring 20% Today?
September 27, 2022
Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 27, 2022
Gainers
Via
Benzinga
This Analyst Boosts PT On PepsiCo? Plus UBS Sees $75 For Micron Technology
September 27, 2022
Deutsche Bank raised the price target on PepsiCo, Inc. (NASDAQ: PEP) from $179 to $181. Deutsche Bank analyst Steve Powers maintained a Hold rating on the stock. PepsiCo shares fell 1.2% to $166.47 on...
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
September 27, 2022
Gainers
Via
Benzinga
Here's Why Equillium Stock Is Skyrocketing
September 27, 2022
Equillium Inc (NASDAQ: EQ) shares are trading higher by 23.32% to $2.38 Tuesday morning after the company reported interim results from the Type B portion of the EQUALISE study evaluating itolizumab....
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 27, 2022
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.
Via
Benzinga
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
September 27, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
September 15, 2022
From
Equillium, Inc.
Via
Business Wire
EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to Shareholders
September 06, 2022
From
Halper Sadeh LLP
Via
Business Wire
Equillium to Acquire Metacrine in All-Stock Transaction
September 06, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
August 31, 2022
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.